Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Summary

This randomized phase II trial studies the side effects and how well Akt inhibitor MK2206 or everolimus works in treating patients with kidney cancer that does not respond to treatment. Akt inhibitor MK2206 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether Akt inhibitor MK2206 or everolimus is more effective in treating kidney cancer.

Timeline

Start

2011-01-27

Primary completion

2018-09-19

Completion

2018-09-19

Drugs

Indications